Can you get medical cannabis for multiple sclerosis in the UK?

Multiple sclerosis is the strongest case on this page, and the only condition here where a cannabis-based medicine is both licensed in the UK and recommended by NICE — for one specific symptom, under specific conditions.

Is multiple sclerosis treated with medical cannabis in the UK?

Yes, for one symptom, on the NHS: moderate to severe spasticity in MS, where other antispasticity medicines have not worked well enough. This is one of only three licensed uses of a cannabis-based medicine in the UK.

NICE guideline NG144 recommends the THC:CBD oromucosal spray for this purpose, with conditions attached. Treatment must be started and supervised by a doctor with specialist expertise in MS spasticity. It runs as a four-week trial, and is continued only if the person's spasticity-related symptoms improve by at least 20% on a patient-reported scale. If they do not, it is stopped.

Other MS symptoms sit outside that licence. Neuropathic pain in MS, bladder dysfunction, tremor, fatigue and sleep problems are assessed by private specialists case by case, on much weaker evidence, in the same way as any other unlicensed use.

None of this is disease-modifying treatment. Cannabis-based medicines do not slow MS progression or reduce relapses, and your neurology team should continue to lead that side of your care.

What the evidence actually shows

MS spasticity has the evidence base the rest of this field lacks: multiple randomised controlled trials, a regulatory licence, and a NICE recommendation. That is why the NHS position on MS is different from its position on everything else.

The pivotal trial used an enriched design — a single-blind run-in phase identified people who responded to the spray, and only those responders were randomised to continue on it or switch to placebo. Among that responder group, the spray was significantly better than placebo on spasticity scores. That design answers a specific question well: does it keep working in people it works for? It also explains the four-week trial rule in NICE guidance. Roughly speaking, it does not help most people who try it, and helps a minority meaningfully — so the sensible policy is to try it briefly and stop unless there is a clear response.

Evidence for other MS symptoms is much weaker, and a specialist should distinguish clearly between the licensed use and everything else.

What a specialist will want to see

There is no UK list of qualifying conditions, so nothing here entitles you to a prescription. A specialist works through your history and decides whether a monitored trial is justified for you. For multiple sclerosis they will typically look at:

• Whether spasticity is your main problem, and how it affects movement, sleep and pain
• Which antispasticity treatments you have tried — baclofen, tizanidine, gabapentin, physiotherapy, botulinum toxin
• Whether your MS team can start the licensed treatment on the NHS, which is often the better route
• Your disease-modifying therapy and who manages it
• Which other symptoms matter to you, and whether they fall inside or outside the licensed use
• Your mobility, falls risk and cognition, since sedation carries more consequence in MS

The general requirements — age, a documented diagnosis, the convention that two standard treatments have been tried, and access to your medical records — are covered in What are the requirements?

Risks and reasons a specialist may say no

Dizziness and fatigue are common with the licensed spray and matter more in MS, where balance and fatigue are often already impaired. Falls are a real consideration.

Cognitive effects deserve attention too: MS itself can affect processing speed and memory, and THC-containing medicines can add to that. A personal or family history of psychosis, unstable serious mental illness, pregnancy and breastfeeding all count against treatment. Driving impairment applies as it does elsewhere, and MS-related visual or motor problems may already affect fitness to drive independently.

How medical cannabis is thought to help

Cannabis-based medicines act on the endocannabinoid system, a signalling network found throughout the brain, nervous system and immune cells that helps regulate muscle tone, pain, mood, sleep and inflammation. That broad role is why these medicines are studied across such different conditions — but a plausible mechanism is not the same as proven benefit, and the two should not be confused.

The two most studied plant compounds behave very differently. THC is intoxicating and acts directly on cannabinoid receptors; cannabidiol (CBD) is not intoxicating and works more indirectly. In MS spasticity it is a balanced combination of THC and CBD that carries the licence, not CBD alone. Our guides on the endocannabinoid system and THC and CBD explain the difference in more detail.

Spasticity is excessive muscle tone and involuntary stiffness caused by damage to nerve pathways, and cannabinoid receptors are present in the parts of the nervous system that help control it. That is the general rationale for the licensed use — but it is a treatment for the symptom, not for the underlying multiple sclerosis.

What treatment involves in practice

If treatment is appropriate for you, it follows a consistent pattern. It starts at a low dose and is increased slowly — titrated — while you and the specialist track benefit against side effects. There is no fixed dose that suits everyone, and in MS the balance against dizziness, fatigue and falls is watched closely.

The licensed treatment for MS spasticity is a THC:CBD oromucosal spray, started and supervised by a specialist in MS spasticity, and continued only if there is a clear response within the first weeks. Where other MS symptoms are treated privately, products are usually oils or capsules taken by mouth, or dried flower for vaporising; smoking is never a medical route. How the format and dose are chosen is set out in how a dose is decided and adjusted and how cannabis-based medicines are taken.

Follow-up reviews check how you are responding and whether side effects are tolerable, and the plan is adjusted — or stopped — accordingly. Benefit is judged over weeks rather than a single dose, as how long cannabis medicines take to work explains. Treatment that is not clearly helping is stopped rather than continued indefinitely, and your disease-modifying therapy continues under your neurology team throughout.

Questions worth asking your specialist

A good assessment is a two-way conversation. Whether treatment turns out to suit you or not, these are sensible questions to bring, alongside the practical guides on driving, work and drug testing, and travelling abroad:

• Is my spasticity the licensed use, and could my MS team start the spray on the NHS instead?
• Which symptom are we trying to improve, and how will we measure whether it is working?
• How will this affect my balance, fatigue and falls risk, given my MS?
• How will it interact with my current medicines and my disease-modifying therapy?
• At what point would we agree the treatment is not helping and stop it?

If you want to take this further

The useful next step is a proper assessment, not a better list. Gather your diagnosis, the treatments you have already tried and what happened with each, and your current medicines — that is what a specialist needs in order to give you a straight answer.

The consultation itself, and what happens after it, is set out in What is the process to get a medical cannabis prescription? If multiple sclerosis is not the only thing you are being treated for, say so early: other conditions and other medicines change the assessment.

Patient guide · Written by the Flora House editorial team · Last reviewed: 7 October 2026